SynAct Pharma doses first subject in study with new AP1189 tablets
SynAct Pharma AB (“SynAct”) today announced that the first subject has been dosed in a clinical study in healthy volunteers to describe the pharmacokinetics of AP1189 following administration of a new tablet formulation aimed for once daily dosing in further clinical development of the compound.The study is a single center, open label, 3-part pharmacokinetic study, with 12 healthy subjects in each part. The primary objective of the first part is to determine the relative bioavailability of AP1189 after dosing with the newly developed tablets versus the oral suspension used so far in